Stock NPCE NEUROPACE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News NeuroPace, Inc.

Equities

NPCE

US6412881053

Delayed Nasdaq
Other stock markets
 11:36:39 2024-06-05 am EDT 		5-day change 1st Jan Change
6.535 USD +1.00% Intraday chart for NeuroPace, Inc. -3.04% -36.61%
May. 13 Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating MT
May. 08 NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroPace to Participate in Two Healthcare Conferences in May
AQ
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
MT
NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : NeuroPace, Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $18.1M, vs. Street Est of $17.3M
MT
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024
CI
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
GL
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
AQ
North American Morning Briefing : Inflation -2-
DJ
Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16
MT
JPMorgan Adjusts Price Target on NeuroPace to $17 From $9, Maintains Overweight Rating
MT
NeuroPace Shares Decline Following Q4 Financial Results
MT
NeuroPace, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : NeuroPace, Inc., Q4 2023 Earnings Call, Mar 05, 2024
NeuroPace, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M
MT
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
GL
NeuroPace, Inc. Provides Earnings Guidance for the Year 2024
CI
Wells Fargo Increases Price Target on NeuroPace to $16 From $9, Maintains Equalweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NPCE Stock
  4. News NeuroPace, Inc.